SCHEMBL267643

SCHEMBL267643

Cc1ccc(C=NNC(=O)c2cc(Br)ccc2NC(=O)c2cccnc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.57
MEN1 O00255 6/20 0.57
NPC1 O15118 3/20 0.57
RAB9A P51151 3/20 0.57
POLB P06746 5/20 0.55
ALDH1A1 P00352 3/20 0.55
MAPT P10636 3/20 0.55
GAA P10253 1/20 0.53
TDP1 Q9NUW8 2/20 0.53
PSMD14 O00487 1/20 0.53
IDE P14735 1/20 0.52
LMNA P02545 2/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
PKM P14618 1/20 0.51
KDM4E B2RXH2 1/20 0.50
HPGD P15428 1/20 0.50
CASP6 P55212 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL267642 1.00 KMT2A (0.57) KMT2AMEN1NPC1RAB9APOLB
Hydrochloric Acid SCHEMBL267009 0.99 KMT2A (0.56) KMT2AMEN1NPC1RAB9APOLB
Hydrochloric Acid SCHEMBL267008 0.99 KMT2A (0.56) KMT2AMEN1NPC1RAB9APOLB
SCHEMBL266291 0.91 KMT2A (0.55) KMT2AMEN1NPC1RAB9APOLB
SCHEMBL266292 0.91 KMT2A (0.55) KMT2AMEN1NPC1RAB9APOLB
SCHEMBL268677 0.91 KMT2A (0.57) KMT2AMEN1NPC1RAB9APOLB
SCHEMBL268676 0.91 KMT2A (0.57) KMT2AMEN1NPC1RAB9APOLB
SCHEMBL266918 0.90 GAA (0.59) KMT2AMEN1NPC1RAB9APOLB
SCHEMBL266917 0.90 GAA (0.59) KMT2AMEN1NPC1RAB9APOLB
SCHEMBL268847 0.89 KMT2A (0.55) KMT2AMEN1NPC1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 KMT2A 4564/4885MEN1 1194/4885NPC1 102/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 KMT2A 4603/4885MEN1 1638/4885NPC1 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.